Medidata Solutions today announced that Orion Corporation has
chosen to standardize on Medidata Rave as its global electronic data
capture (EDC) management and reporting solution. This year, Orion
plans to use Rave for most of the clinical studies throughout Europe.
With an ultimate goal of eliminating paper-based clinical processes,
Orion expects all of the company's trials will be managed by Medidata
Rave within the next few years.
Widely recognized for its groundbreaking Parkinson's therapies,
Orion is a mid-sized, Finland-based pharmaceutical company which
develops treatments in cardiology and critical care, central nervous
system diseases and hormonal and urological disorders. In 2005, the
company decided to replace its paper-based processes with a
user-friendly electronic data capture and management solution that
would improve efficiencies and decrease time to market. As a result,
Orion conducted a year-long, in-depth evaluation of five leading EDC
vendors and narrowed down their decision to three major vendors in the
space.
Orion's selection of Medidata Rave was due to its flexible
implementation and knowledge transfer process as well as the ability
to analyze data in real-time. Orion was also impressed with the
product's ease of use and ability to foster communication between site
and sponsor.
"From a cost-benefit perspective, Medidata Rave offers significant
advantages, and we were impressed with the product's functionality
across all levels of clinical data management. Medidata Rave allows
our own staff and partners to coordinate and manage information
through quick access to clean, real-time data - even in remote
locations," said Taru Blom, Director of Clinical Research &
Development at Orion. "Our ultimate goal is to complete a full
knowledge transfer so we can manage most of the activities of Rave
in-house by the end of 2007."
Orion begins its first study using Medidata Rave in April of 2007
and expects to see immediate benefits.
"Medidata Rave's flexible technology and ability to easily
interface with other applications allows us to easily evolve our
clinical trial processes and tailor our studies in new ways," said
Olavi Kilkku, Director of Biostatistics and Data Management at Orion.
"With adaptive clinical trials on the horizon, Medidata Rave is a
critical component to putting methods into place now that will bring
us closer to fulfilling our future goals."
"Medidata's services and support team looks forward to working
with Orion's clinical and data management staff to enable them with
the tools and training they need to implement and maintain Medidata
Rave in-house," said Tarek Sherif, CEO of Medidata Solutions. "Orion's
decision to standardize on Medidata Rave shows their commitment to
enhancing clinical trials technology, and we look forward to helping
the company reach their clinical goals in an efficient and
cost-effective way."
About Orion Corporation
Orion Corporation, founded in 1917, is a Finnish listed company
which develops, manufactures and markets pharmaceuticals, active
pharmaceutical ingredients and diagnostic tests for global markets.
Orion's major therapy areas relate to central nervous system diseases,
cardiovascular diseases and critical care, and hormonal and urological
therapies. Its biggest selling products are Stalevo(R) and
Comtess(R)/Comtan(R), both for Parkinson's Disease, and it is the
leader in the animal health market for the Nordic countries. Orion is
listed on the Helsinki Stock Exchange (symbols ORNAV and ORNBV). For
more information about Orion, go to www.orion.fi/english.
About Medidata Solutions Worldwide
Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.
